Patents by Inventor Ian Holmes
Ian Holmes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250066416Abstract: The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with viral or bacterial infections.Type: ApplicationFiled: October 30, 2024Publication date: February 27, 2025Inventors: David Jackson, Ian Holmes, Weiguang Zeng, Christophe Demaison
-
Patent number: 12195557Abstract: The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with viral or bacterial infections.Type: GrantFiled: December 21, 2018Date of Patent: January 14, 2025Assignee: AXELIA ONCOLOGY PTY LTDInventors: David Jackson, Ian Holmes, Weiguang Zeng, Christophe Demaison
-
Patent number: 12157777Abstract: The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with viral or bacterial infections.Type: GrantFiled: December 21, 2018Date of Patent: December 3, 2024Assignee: AXELIA ONCOLOGY PTY LTDInventors: David Jackson, Ian Holmes, Weiguang Zeng, Christophe Demaison
-
Patent number: 12017979Abstract: The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with viral or bacterial infections.Type: GrantFiled: March 23, 2023Date of Patent: June 25, 2024Assignee: ENA Respiratory Pty LtdInventors: Ian Holmes, Weiguang Zeng, David Jackson, Christophe Demaison, Grant McLachlan
-
Publication number: 20230257345Abstract: The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with viral or bacterial infections.Type: ApplicationFiled: March 23, 2023Publication date: August 17, 2023Inventors: Ian Holmes, Weiguang Zeng, David Jackson, Christophe Demaison, Grant McLachlan
-
Patent number: 11643429Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory/infections disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugate which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eye, ocular surface or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.Type: GrantFiled: April 5, 2021Date of Patent: May 9, 2023Assignee: AZURA OPHTHALMICS LTD.Inventors: Ian Holmes, Yair Alster, Hila Barash, Charles Bosworth, Omer Rafaeli, Marc Gleeson, Mark Richard Stewart, Jonathan Dunn
-
Patent number: 11634411Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.Type: GrantFiled: December 4, 2020Date of Patent: April 25, 2023Assignee: AZURA OPHTHALMICS LTD.Inventors: Ian Holmes, Yair Alster, Hila Barash, Charles Bosworth, Omer Rafaeli, Marc Gleeson, Mark Richard Stewart, Robert M. Burk, Jonathan Dunn, Nicholas Chapman
-
Publication number: 20220388950Abstract: The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with viral or bacterial infections.Type: ApplicationFiled: June 26, 2020Publication date: December 8, 2022Inventors: Ian Holmes, Weiguang Zeng, David Jackson, Christophe Demaison, Grant Mclachlan
-
Patent number: 11459351Abstract: Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.Type: GrantFiled: April 5, 2021Date of Patent: October 4, 2022Assignee: AZURA OPHTHALMICS LTD.Inventors: Ian Holmes, Yair Alster, Hila Barash, Charles Bosworth, Omer Rafaeli, Robert M. Burk, Marc Gleeson, Mark Richard Stewart, Jonathan Dunn, Alexander James Nicholls
-
Publication number: 20210230217Abstract: The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with viral or bacterial infections.Type: ApplicationFiled: December 21, 2018Publication date: July 29, 2021Inventors: David Jackson, Ian Holmes, Weiguang Zeng, Christophe Demaison
-
Patent number: 10875845Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.Type: GrantFiled: June 17, 2020Date of Patent: December 29, 2020Assignee: AZURA OPHTHALMICS LTD.Inventors: Ian Holmes, Yair Alster, Hila Barash, Charles Bosworth, Omer Rafaeli, Marc Gleeson, Mark Richard Stewart, Robert M. Burk, Jonathan Dunn, Nicholas Chapman
-
Patent number: 10726123Abstract: Malicious activity can be detected and prevented in real-time or otherwise. For example, a system of the present disclosure can receive a request from a user to obtain access to an entity, determine data objects based on the request, and access data-object network definitions corresponding to the determined data objects. The system can also receive a profile for the user indicating behavioral information relating to the user. The system can then determine a likelihood that the request is associated with malicious activity based on (i) the data objects, (ii) the profile, and (iii) the data-object network definitions. The system can allow or deny the user access to the entity based on the likelihood that the request is associated with malicious activity.Type: GrantFiled: April 15, 2020Date of Patent: July 28, 2020Assignee: SAS INSTITUTE INC.Inventors: Prathaban Mookiah, Ian Holmes, John Robert Watkins, Thomas J. O'Connell
-
Publication number: 20170226133Abstract: A compound of formula (I): for use in the prevention or treatment of a bacterial infection wherein: A is either S or Se; RA is selected from: wherein: each of Y1, Y2, Y3, Y4 and Y9 is independently selected from CH or N, wherein at least three of Y1, Y2, Y3, Y4 and Y9 is CH; V is selected from O, CH—OR01, N—CO2—RC2 or N—RN2; one of Y5, Y6, Y7 and Y8 is selected from CH and N, and the others are CH; X is selected from NH, S or O; RC1 is selected from O—RO2 or NHRN1; RO1 is selected from H and C1-3 unbranched alkyl; RO2 is C1-3 unbranched alkyl; RN1 is selected from H and C1-3 unbranched alkyl; RN2 is C1-3 unbranched alkyl; RC2 is either C1-3 unbranched alkyl or C3-4 branched alkyl; RC3 is selected from C1-3 unbranched alkyl and C2H4CO2H; RC4 is either H or Me; RC5 is either H or Me; RC6 represents one or two optional methyl substituents; and n is an integer from 2 to 8.Type: ApplicationFiled: May 28, 2015Publication date: August 10, 2017Applicant: Auspherix LimitedInventors: Ian Holmes, Alan Naylor, Gabriel Negoita-Giras, Jonathan Powell, Ian Charles, Albert Dagmar
-
Publication number: 20170204123Abstract: A compound of formula (I) for use in the prevention or treatment of a bacterial infection wherein RP1 is either methyl, ethyl, isopropyl, cyclohexyl or phenyl; RP2 is selected from methyl, ethyl, isopropyl, cyclohexyl and phenyl; RP3 is either ethyl, isopropyl, cyclohexyl, phenyl or pyridyl; A is either S or Se; RA is selected from wherein each of Y1, Y2, Y3, Y4 and Y9 is independently selected from CH or N, wherein at least three of Y1, Y2, Y3, Y4 and Y9 are CH; V is selected from O, CH—ORO1, N—CO2—RC2 or N—RN2; one of V, Y6, Y7 and Y8 is selected from CH and N, and the others are CH; X is selected from NH, S or O; RC1 is selected from O—RO2 or NHRN1; RO1 is selected from H and C1-3 unbranched alkyl; RO2 is C1-3 unbranched alkyl; RN1 is selected from H and C1-3 unbranched alkyl; RN2 is C1-3 unbranched alkyl; RC2 is either C1-3 unbranched alkyl or C3-4 branched alkyl; RC3 is selected from C1-3 unbranched alkyl and C2H4CO2H; RC4 is either H or Me; RC5 is either H or Me; RC6 represents one or two optional methyType: ApplicationFiled: May 28, 2015Publication date: July 20, 2017Inventors: Ian Holmes, Alan Naylor, Gabriel Negoita-Giras, Jonathan Powell, Ian Charles, Albert Dagmar
-
Patent number: 8286480Abstract: A positive displacement fluid flow meter comprises a chamber having a fluid inlet and a fluid outlet. A rotor is displaceable within the chamber, rotation of the rotor being related to the volume of fluid passing through the chamber. The chamber has a surface proximate which an end surface of the rotor passes, the chamber surface and/or the rotor end surface having at least one recess to retain at least a portion of debris carried by the metered fluid. The recess is preferably formed so as not to provide fluid, communication, from the inlet to the outlet across the rotor end surface. A lid closes an end of the chamber which in use is subject to the pressure of fluid within the chamber. The lid is engaged at its periphery to a wall of the chamber, and is preferably flexible adjacent its periphery to reduce the transmission of bending stresses between the periphery of the lid and the remainder thereof.Type: GrantFiled: August 10, 2006Date of Patent: October 16, 2012Assignee: Elster Metering LimitedInventors: Ian Holmes-Higgin, Ian Young, Ivor Rogers
-
Publication number: 20100300199Abstract: A positive displacement fluid flow meter comprises a chamber having a fluid inlet and a fluid outlet. A rotor is displaceable within the chamber, rotation of the rotor being related to the volume of fluid passing through the chamber. The chamber has a surface proximate which an end surface of the rotor passes, the chamber surface and/or the rotor end surface having at least one recess to retain at least a portion of debris carried by the metered fluid. The recess is preferably formed so as not to provide fluid, communication, from the inlet to the outlet across the rotor end surface. A lid closes an end of the chamber which in use is subject to the pressure of fluid within the chamber. The lid is engaged at its periphery to a wall of the chamber, and is preferably flexible adjacent its periphery to reduce the transmission of bending stresses between the periphery of the lid and the remainder thereof.Type: ApplicationFiled: August 10, 2006Publication date: December 2, 2010Applicant: ELSTER METERING LIMITEDInventors: Ian Holmes Higgin, Ian Young, Ivor Rogers
-
Publication number: 20090235816Abstract: A filtering apparatus (50) for removing noxious gases from an environment including: a source of compressed gas (60) connected to a regulating valve (62) to regulate a supply of compressed gas; at least one airflow device (5) including a compressed gas inlet (10) for receiving gas from the supply of compressed gas at greater than ambient atmospheric pressure, the gas inlet (10) being operably connected to the regulating valve (62); and a permeable noxious gas filter (55) arranged in gaseous communication with the airflow device (5); wherein the supply of compressed gas to the airflow device (5) causes the airflow device (5) to draw ambient air (64) from the environment through a primary intake (42), thereby generating a flow of air through the noxious gas filter (55) and causing the substantial removal of noxious gases from the flow of air.Type: ApplicationFiled: September 26, 2008Publication date: September 24, 2009Inventors: Anthony FARRUGIA, Ernest James Benson, David Ian Holm
-
Patent number: 7476759Abstract: Compounds of Formula (I): wherein: R1 is optionally substituted —C4-12 alkyl, —C2-10alkylcycloalkyl, —C2-6alkylheterocycloalkyl, —C2-6alkylaryl, optionally substituted 5- or 6-membered aryl or heteroaryl with the proviso that R2 in not pyridinyl; Z is a bond, CH2, O, S, SO, SO2, NR4, OCR4R5 or CR4R5O; or Z, R1 and Q together form an optionally substituted fused tricyclic group; Q is an optionally substituted 5- or 6-membered aryl or heteroaryl ring; X is COR3; R2 is CONH2, CO2H, CO2R7, SO2R7 or SO2NR8R9, with the proviso that R2 is not CO2R7, when X is CONH2; R3 is OR6 or NR8R9; R4 and R5 each independently is H, C1-6 alkyl or C1-4 alkylaryl; R6 is H or C1-6 alkyl; R7 is C1-6 alkyl; and R8 and R9 each independently is H or C1-6 alkyl; or R8 and R9 together with the nitrogen atom to which they are attached form a 5- or 6-membered ring which may optionally include 1 or more further heteroatoms selected from O, S and N; or physiologically functional derivatives thereof, with the proviso that formula (I) cType: GrantFiled: August 12, 2004Date of Patent: January 13, 2009Assignee: Glaxo Group LimitedInventors: Ian Holmes, Stephen Paul Watson
-
Publication number: 20080227858Abstract: Compounds of formula (I): wherein R1 represents optionally substituted C4-12 alkyl, optionally substituted C2-6alkylaryl, or optionally substituted 5- or 6-membered aryl or heteroaryl; Z represents a bond, CH2, O, S, SO, SO2, NR4, OCR4R5, CR4R5O, or Z, R1 and Q together form an optionally substituted fused tricyclic group; Q represents an optionally substituted 5- or 6-membered aryl or heteroaryl ring; X represents COR3 or N(OR8)COR9; R2 represents SO2R10 or SO2NR10R11; R3 represents OR6NR6R7 or NR6OH; R4 and R5 each independently represents H, C1-6 alkyl or C1-4 alkylaryl; R6 and R7 each independently represents H, C1-6 alkyl, or C1-6 alkyl substituted with one or more heteroaryl groups, or R6 and R7 together with the nitrogen atom to which they are attached form a 5- or 6-membered ring which may optionally include 1 or more further heteroatoms selected from O, S and N; R8 and R9 each independently represents H or C1-6 alkyl; R10 and R11 each independently represents H or C1-6 alkyl; and and physiologicType: ApplicationFiled: May 19, 2008Publication date: September 18, 2008Inventors: Ian Holmes, Stephen Paul Watson
-
Patent number: 7375248Abstract: Compounds of formula (I): wherein R1 represents optionally substituted C4-12 alkyl, optionally substituted C2-6alkylaryl, or optionally substituted 5- or 6-membered aryl or heteroaryl; Z represents a bond, CH2, O, S, SO, SO2, NR4, OCR4R5, CR4R5O, or Z, R1 and Q together form an optionally substituted fused tricyclic group; Q represents an optionally substituted 5- or 6-membered aryl or heteroaryl ring; X represents COR3 or N(OR8)COR9; R2 represents SO2R10 or SO2NR10R11; R3 represents OR6, NR6R7 or NR6OH; R4 and R5 each independently represents H, C1-6 alkyl or C1-4 alkylaryl; R6 and R7 each independently represents H, C1-6 alkyl, or C1-6 alkyl substituted with one or more heteroaryl groups, or R6 and R7 together with the nitrogen atom to which they are attached form a 5- or 6-membered ring which may optionally include 1 or more further heteroatoms selected from O, S and N; R8 and R9 each independently represents H or C1-6 alkyl; R10 and R11 each independently represents H or C1-6 alkyl; and and physioloType: GrantFiled: June 16, 2004Date of Patent: May 20, 2008Assignee: Glaxo Group LimitedInventors: Ian Holmes, Stephen Paul Watson